Genmab A/S
GMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $22 | $16 | $15 | $8 |
| % Growth | 30.7% | 13.6% | 72.3% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $21 | $16 | $15 | $8 |
| % Margin | 95.4% | 98.6% | 100% | 100% |
| R&D Expenses | $10 | $8 | $6 | $4 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $4 | $3 | $3 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $11 | $8 | $5 |
| Operating Income | $7 | $5 | $6 | $3 |
| % Margin | 31.1% | 32.3% | 43.2% | 35.1% |
| Other Income/Exp. Net | $2 | $0 | $1 | $1 |
| Pre-Tax Income | $9 | $6 | $7 | $4 |
| Tax Expense | $1 | $1 | $1 | $1 |
| Net Income | $8 | $4 | $5 | $3 |
| % Margin | 36.4% | 26.4% | 37.6% | 35.1% |
| EPS | 12.14 | 6.6 | 8.34 | 4.52 |
| % Growth | 83.9% | -20.9% | 84.5% | – |
| EPS Diluted | 12.14 | 6.6 | 8.26 | 4.48 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $10 | $6 | $7 | $4 |
| % Margin | 45% | 36.1% | 50.6% | 49.7% |